💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Talaporfin

CHEMBL2111186 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
711.8 g/mol
LogP
3.5
Phase
4

Talaporfin (mono-l-aspartyl chlorin e6) is a second-generation chlorin-based photosensitizer used in photodynamic therapy (PDT) for early-stage central lung cancer, early-stage esophageal cancer, and investigation in AMD and BPH. Upon activation by 664 nm red light, it generates cytotoxic singlet oxygen and reactive oxygen species that induce apoptosis and vascular shutdown in the illuminated target tissue. Its chlorin-based structure provides stronger near-infrared light absorption and shorter drug-to-light intervals than porphyrin-based photosensitizers.

الوزن الجزيئي

711,8000 g/mol

LogP

3,50

TPSA

236,00 Ų

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Benign Prostatic Hyperplasia Age-Related Macular Degeneration Breast Cancer Colorectal Cancer

آلية العمل

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C

                

                

                
                

                    
InChI

                    
InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C38H41N5O9

                    

                    
                    

                        
HBD / HBA

                        
7 / 11

                    

                    
                    

                        
الروابط القابلة للدوران

                        
12

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Talaporfin (mono-l-aspartyl chlorin e6) is a second-generation chlorin-based photosensitizer used in photodynamic therapy (PDT) for early-stage central lung cancer, early-stage esophageal cancer, and investigation in AMD and BPH. Upon activation by 664 nm red light, it generates cytotoxic singlet oxygen and reactive oxygen species that induce apoptosis and vascular shutdown in the illuminated target tissue. Its chlorin-based structure provides stronger near-infrared light absorption and shorter drug-to-light intervals than porphyrin-based photosensitizers.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Talaporfin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2111186.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5486799.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.